RxDoctor Payments Data

Jacob Hayden, MD

Cardiovascular Disease · Jefferson City, MONPI 1871022954

Payments from drug & device makers

$3,318in general payments, 2019–2025

Across 190 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novartis$467
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$358
  • Abbott$212
  • Chiesi USA, Inc.$159
  • AstraZeneca$158
  • plus $589 from 12 others

What the payments were for

  • Food & beverage$3,22297%
  • Gifts$963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,318 in reported general payments places this provider in the 55th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$173,315
Medicare patients
1,164
Services billed
2,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban251$222,044
XareltoRivaroxaban41$53,352
EntrestoSacubitril/Valsartan39$39,626
Repatha SureclickEvolocumab23$19,080
JardianceEmpagliflozin17$15,302
Metoprolol Succinate313$2,681
Rosuvastatin Calcium261$1,790
Losartan Potassium175$1,242
Midodrine Hcl13$745
Amlodipine Besylate173$672
Atorvastatin Calcium82$522
Metoprolol Tartrate120$515
ClopidogrelClopidogrel Bisulfate61$466
Furosemide77$390
Lisinopril74$317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$31$53,35241 claims
NovartisEntresto$467$39,62639 claims
Boehringer IngelheimJardiance$72$15,30217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Jefferson City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →